Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05459259
Other study ID # 22027
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 3, 2022
Est. completion date August 30, 2023

Study information

Verified date November 2022
Source University of Nottingham
Contact Michelle C Hall, PhD
Phone 0115 8231794
Email michelle.hall@nottingham.ac.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research aims to develop an optimal physiotherapy intervention for people with arthrofibrosis (stiffness due to scar tissue) after total knee replacement (TKR). We will develop an optimal intervention by conducting: 1. A review of the evidence to identify what components could be included in the intervention, how effective they are and what outcomes have been measured by the research. 2. Interviews with patients with arthrofibrosis to understand the impact it has on their life and what outcomes are important to them and interviews with healthcare professionals (HCPs) to understand their experiences of treating patients with arthrofibrosis. 3. A Delphi study with a larger group of HCPs and patients to reach a consensus on what the optimal intervention should include. This involves a series of anonymous voting on a range of items that have been generated by the group and the results of the evidence review. 4. A workshop with patients, HCPs and health-care commissioners to finalise the intervention. During the workshop we will present our findings and work in small groups to agree the intervention


Recruitment information / eligibility

Status Recruiting
Enrollment 145
Est. completion date August 30, 2023
Est. primary completion date August 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for Patients: - adults (aged 18 and over) of any age who have undergone elective TKR with post- operative arthrofibrosis/stiffness who have undergone manipulation under anaesthetic (MUA) in the previous 24 months or are currently listed for a MUA. - Ability to give informed consent Exclusion Criteria: - Patients with neurological or blood disorders For HCP participants : - at least 5 years of experience working with joint arthroplasty including the management of patients with arthrofibrosis or 3 years in the case of orthopaedic surgeons.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Interviews and Delphi Survey
no intervention delivered

Locations

Country Name City State
United Kingdom University of Nottingham Nottingham

Sponsors (3)

Lead Sponsor Collaborator
University of Nottingham King's College London, National Institute for Health Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Qualitative interviews with Patients and Healthcare Professionals we will conduct qualitative interviews with patients to explore (i) the experiences, important outcomes and unmet needs of patients; and with health care professionals (HCPs) to understand (ii) their experiences, perceptions and context of managing arthrofibrosis and (iii) their opinions on the intervention components identified in a systematic review of the evidence. 12 months
Primary A Delphi survey with HCPs and patients to achieve consensus agreement on the most important components of an optimal intervention. We will conduct a modified Delphi exercise with a maximum of 4 rounds to agree consensus on (i) the essential components of the intervention and what are the important outcomes that should be collected for patients with arthrofibrosis . 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05570058 - Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979417 - Identification of Biomarkers Related to Liver Fibrosis as New Therapeutic Targets
Completed NCT02408744 - Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease Phase 1/Phase 2
Active, not recruiting NCT00148837 - Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis Phase 2
Recruiting NCT05661123 - Effect of Modified Complete Decongestive Therapy on Lower Limbs Fibrosis Post Cellulitis N/A
Recruiting NCT04795570 - Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
Active, not recruiting NCT05075785 - Covid-19 Respiratory Sequelae French Cohort
Recruiting NCT03308916 - Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers N/A
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00001729 - Combination Drug Therapy for Patients With Hepatitis C Phase 3
Completed NCT02049307 - Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial Phase 2
Active, not recruiting NCT05685823 - The Impact of Conventional Hemodialysis and Renal Transplantation on the Global Longitudinal Strain of the Left Ventricle
Completed NCT00744939 - Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist Phase 4
Completed NCT00252642 - Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C N/A
Recruiting NCT04934202 - Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France
Completed NCT02774161 - B-mode Ultrasound Imaging in Detecting Early Liver Cancer N/A
Completed NCT02604862 - Imaging FIB ONE in the Human Lung Using Endomicroscopy Early Phase 1
Active, not recruiting NCT01246388 - Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy N/A
Completed NCT02161952 - Pirfenidone, an Antifibrotic and Antiinflammatory Drug Phase 2
Completed NCT00347009 - Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis Phase 4